NASDAQ:ESPR Esperion Therapeutics (ESPR) Stock Price, News & Analysis $1.65 -0.07 (-4.07%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$1.63▼$1.7350-Day Range$1.65▼$2.7352-Week Range$0.70▼$3.40Volume2.76 million shsAverage Volume6.86 million shsMarket Capitalization$312.61 millionP/E RatioN/ADividend YieldN/APrice Target$8.17 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Esperion Therapeutics alerts: Email Address Esperion Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.25 Rating ScoreUpside/Downside394.9% Upside$8.17 Price TargetShort InterestBearish21.50% of Float Sold ShortDividend StrengthN/ASustainability-2.76Upright™ Environmental ScoreNews Sentiment0.70Based on 4 Articles This WeekInsider TradingSelling Shares$280 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.04) to $0.39 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.40 out of 5 starsMedical Sector269th out of 910 stocksPharmaceutical Preparations Industry113th out of 426 stocks 3.1 Analyst's Opinion Consensus RatingEsperion Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 2 buy ratings, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageEsperion Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Esperion Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted21.50% of the float of Esperion Therapeutics has been sold short.Short Interest Ratio / Days to CoverEsperion Therapeutics has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in Esperion Therapeutics has recently increased by 9.41%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldEsperion Therapeutics does not currently pay a dividend.Dividend GrowthEsperion Therapeutics does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEsperion Therapeutics has received a 53.54% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Ezetimibe", "Clinical research services for pulmonary hearth diseases", and "Bempedoic acid" products. See details.Environmental SustainabilityThe Environmental Impact score for Esperion Therapeutics is -2.76. Previous Next 2.6 News and Social Media Coverage News SentimentEsperion Therapeutics has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Esperion Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 13 people have searched for ESPR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Esperion Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Esperion Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $280.00 in company stock.Percentage Held by InsidersOnly 1.00% of the stock of Esperion Therapeutics is held by insiders.Percentage Held by Institutions47.39% of the stock of Esperion Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Esperion Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Esperion Therapeutics are expected to grow in the coming year, from ($0.04) to $0.39 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Esperion Therapeutics is -1.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Esperion Therapeutics is -1.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Esperion Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… Click here now and learn how to prepare. About Esperion Therapeutics Stock (NASDAQ:ESPR)Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.Read More ESPR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ESPR Stock News HeadlinesSeptember 5 at 10:49 AM | finance.yahoo.comEsperion to Participate in Upcoming 2024 Cantor Global Healthcare ConferenceSeptember 4 at 1:41 AM | americanbankingnews.comStockNews.com Downgrades Esperion Therapeutics (NASDAQ:ESPR) to HoldSeptember 7, 2024 | Paradigm Press (Ad)Kamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… September 3, 2024 | globenewswire.comEsperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)August 28, 2024 | americanbankingnews.comStockNews.com Upgrades Esperion Therapeutics (NASDAQ:ESPR) to BuyAugust 26, 2024 | globenewswire.comEsperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment ConferenceAugust 19, 2024 | seekingalpha.comEsperion Therapeutics: Delivering On Expectations While Navigating OverhangsAugust 16, 2024 | seekingalpha.comEsperion Therapeutics: Strategically Positioned To GrowSeptember 7, 2024 | Paradigm Press (Ad)Kamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… August 15, 2024 | uk.finance.yahoo.comEsperion Therapeutics, Inc. (0ET.F)August 14, 2024 | seekingalpha.comEsperion Therapeutics, Inc. (ESPR) Q2 2024 Earnings Call TranscriptAugust 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for Esperion on Robust Revenue Growth and Enhanced Market AccessAugust 13, 2024 | finance.yahoo.comQ2 2024 Esperion Therapeutics Inc Earnings CallAugust 13, 2024 | msn.comBiggest stock movers today: ESPR and HUMAAugust 12, 2024 | finanznachrichten.deEsperion Therapeutics, Inc.: Esperion Reports Second Quarter 2024 Financial Results and Provides a Business UpdateAugust 12, 2024 | investorplace.comESPR Stock Earnings: Esperion Therapeutics Beats EPS, Beats Revenue for Q2 2024August 12, 2024 | globenewswire.comEsperion Reports Second Quarter 2024 Financial Results and Provides a Business UpdateAugust 11, 2024 | markets.businessinsider.comEsperion Therapeutics earnings: here's what to expectSee More Headlines Receive ESPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Esperion Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/12/2024Today9/07/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ESPR CUSIPN/A CIK1434868 Webwww.esperion.com Phone(734) 887-3903FaxN/AEmployees200Year FoundedN/APrice Target and Rating Average Stock Price Target$8.17 High Stock Price Target$16.00 Low Stock Price Target$2.50 Potential Upside/Downside+394.9%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-209,250,000.00 Net Margins-35.46% Pretax Margin-35.46% Return on EquityN/A Return on Assets-15.71% Debt Debt-to-Equity RatioN/A Current Ratio1.97 Quick Ratio1.49 Sales & Book Value Annual Sales$277.79 million Price / Sales1.13 Cash FlowN/A Price / Cash FlowN/A Book Value($1.75) per share Price / Book-0.94Miscellaneous Outstanding Shares189,460,000Free Float187,565,000Market Cap$312.61 million OptionableOptionable Beta1.02 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Sheldon L. Koenig (Age 58)President, CEO & Director Comp: $1.28MDr. JoAnne Micale Foody FACC (Age 59)M.D., Chief Medical Officer Comp: $856.87kMr. Eric J. Warren R.Ph. (Age 52)Chief Commercial Officer Comp: $718.86kMr. Benjamin Halladay M.B.A. (Age 38)Chief Financial Officer Mr. Glenn P. Brame (Age 66)Chief Technical Operations Officer Mr. Benjamin O. Looker J.D. (Age 42)General Counsel & Corporate Secretary Comp: $550.35kTiffany Aldrich M.B.A.Associate Director of Corporate CommunicationsMs. Betty Jean SwartzChief Business OfficerMore ExecutivesKey CompetitorsRadius RecyclingNASDAQ:RDUSOmerosNASDAQ:OMERCara TherapeuticsNASDAQ:CARATango TherapeuticsNASDAQ:TNGXDisc MedicineNASDAQ:IRONView All CompetitorsInsiders & InstitutionsPoint72 Asset Management L.P.Bought 60,000 shares on 8/19/2024Ownership: 0.000%The Manufacturers Life Insurance Company Bought 71,488 shares on 8/15/2024Ownership: 0.038%Deerfield Management Company L.P. Series CBought 66,588 shares on 8/15/2024Ownership: 0.035%Mackenzie Financial CorpBought 18,036 shares on 8/15/2024Ownership: 0.019%Bank of Montreal CanBought 3,000 shares on 8/14/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions ESPR Stock Analysis - Frequently Asked Questions How have ESPR shares performed this year? Esperion Therapeutics' stock was trading at $2.99 at the start of the year. Since then, ESPR stock has decreased by 44.8% and is now trading at $1.65. View the best growth stocks for 2024 here. How were Esperion Therapeutics' earnings last quarter? Esperion Therapeutics, Inc. (NASDAQ:ESPR) announced its quarterly earnings data on Monday, August, 12th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.10. The biopharmaceutical company had revenue of $73.83 million for the quarter, compared to analysts' expectations of $51.90 million. What is Tim Mayleben's approval rating as Esperion Therapeutics' CEO? 20 employees have rated Esperion Therapeutics Chief Executive Officer Tim Mayleben on Glassdoor.com. Tim Mayleben has an approval rating of 80% among the company's employees. Who are Esperion Therapeutics' major shareholders? Esperion Therapeutics' top institutional shareholders include Great Point Partners LLC (3.06%), Marshall Wace LLP (2.27%), Renaissance Technologies LLC (0.75%) and Bank of New York Mellon Corp (0.30%). Insiders that own company stock include Sheldon L Koenig, Eric Warren, Joanne M Foody, Benjamin Looker and J Martin Carroll. View institutional ownership trends. How do I buy shares of Esperion Therapeutics? Shares of ESPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Esperion Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Esperion Therapeutics investors own include ALDW (ALDW), Targa Resources (TRGP), Navios Maritime Partners (NMM), NVIDIA (nvda), Micron Technology (MU), SFL (SFL) and Gilead Sciences (GILD). This page (NASDAQ:ESPR) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Esperion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Esperion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ESPR Stock Alerts